XBiotech (XBIT) Announces DSMB Recommendation to Continue Xilonix Phase 3 in Symptomatic Colorectal Cancer
Tweet Send to a Friend
XBiotech (NASDAQ: XBIT) announced that the Data Safety Monitoring Board (DSMB) has recommended continuation of the Company's Phase 3 registration ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
